Literature DB >> 8797541

Clinical outcomes assessment in multiple sclerosis.

R Rudick1, J Antel, C Confavreux, G Cutter, G Ellison, J Fischer, F Lublin, A Miller, J Petkau, S Rao, S Reingold, K Syndulko, A Thompson, J Wallenberg, B Weinshenker, E Willoughby.   

Abstract

This article represents initial deliberation of an international task force appointed by the US National Multiple Sclerosis Society to develop recommendations for optimal clinical assessment tools for multiple sclerosis clinical trials. Presented within this article are the key issues identified by the task force during its initial year of deliberation. These include the precise purpose for a clinical assessment tool, the clinical dimensions to be measured in a multidimensional outcome measure, desirable attributes of an optimal clinical outcome measure, the complexities of multidimensional outcome measures, the relative merits of categorical clinical ratings and quantitative functional assessments, and a number of other important design issues that relate to the use of a multidimensional outcome measure. An action plan for analysis of existing data is summarized, as are the plans for more detailed recommendations from the task force.

Entities:  

Mesh:

Year:  1996        PMID: 8797541     DOI: 10.1002/ana.410400321

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  33 in total

1.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

2.  A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus.

Authors:  Douglas D Gunzler; Nathan Morris
Journal:  Stat Med       Date:  2015-06-04       Impact factor: 2.373

3.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.

Authors:  N Tubridy; H J Ader; F Barkhof; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

Review 4.  Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis.

Authors:  M Swash
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

Review 5.  Multiple Sclerosis Functional Composite.

Authors:  Serkan Demir
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

6.  Heterogeneous depression trajectories in multiple sclerosis patients.

Authors:  Douglas D Gunzler; Nathan Morris; Adam Perzynski; Daniel Ontaneda; Farren Briggs; Deborah Miller; Robert A Bermel
Journal:  Mult Scler Relat Disord       Date:  2016-08-05       Impact factor: 4.339

7.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 8.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

Review 9.  Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection.

Authors:  Reiko E Sakai; Daniel J Feller; Kristin M Galetta; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2011-12       Impact factor: 3.042

10.  Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients.

Authors:  Maura Pugliatti; Trond Riise; Monica W Nortvedt; Giovanni Carpentras; M Alessandra Sotgiu; Stefano Sotgiu; Giulio Rosati
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.